Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Sponsor
Singapore General Hospital
Study ID
NCT03212807
Phase
PHASE2
Status
Withdrawn

Conditions

  • EBV Related Non-Hodgkin's Lymphoma
  • Primary CNS Lymphoma
  • Primary Testicular Lymphoma

Eligibility Criteria

Sex
ALL
Age
21 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Investigational Medicinal Product
  • Lenalidomide — DRUG
    Investigational Medicinal Product

Study Details

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who fulfill the inclusion / exclusion criteria will be recruited to this trial and treated in this open label, phase 2 trial with the PDL1 inhibitor Durvalumab and Lenalidomide. The combination treatment will be given from the time of recruitment for 6 months when Lenalidomide will be stopped but Durvalumab will continue for a total of 2 years. Response will be assessed by PET / CT scans as per standard lugano criteria.

Key Dates

First listed
Jul 11, 2017
Start date
Aug 31, 2017
Status verified
Sep 2018
Primary completion
Feb 28, 2021
Completion
Aug 31, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Investigational
    Durvalumab + Lenalidomide

Primary Outcome Measure

Overall Response Rate [ Time Frame: at least 6 months of follow up ]

Related Studies